DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease

Phase 2

Completed

Conditions: Diabetic Kidney Disease

Interventions: Drug: Selonsertib
Drug: Placebo to match selonsertib

First Posted Date: 2014-06-30

Last Posted Date: 2019-11-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 334

Registration Number: NCT02177786

Locations: 🇺🇸
Northwest Louisiana Nephrology, Shreveport, Louisiana, United States
🇺🇸
Pines Clinical Research Inc., Pembroke Pines, Florida, United States
🇺🇸
Florida Pulmonary Research Institute, Winter Park, Florida, United States

and more 98 locations

Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo to match GS-5745
Drug: GS-5745

First Posted Date: 2014-06-27

Last Posted Date: 2015-06-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 18

Registration Number: NCT02176876

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF
Drug: RBV

First Posted Date: 2014-06-26

Last Posted Date: 2019-04-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 106

Registration Number: NCT02175758

Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Tenofovir disoproxil fumarate
Biological: GS-4774

First Posted Date: 2014-06-25

Last Posted Date: 2019-06-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 195

Registration Number: NCT02174276

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Kaiser Permanente, Springfield, Virginia, United States
🇺🇸
Research and Education, Inc., San Diego, California, United States

and more 28 locations

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Placebo
Drug: Vesatolimod

First Posted Date: 2014-06-18

Last Posted Date: 2020-10-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 162

Registration Number: NCT02166047

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 2

Withdrawn

Conditions: Triple-negative Breast Cancer

Interventions: Drug: IMMU-132 infusion is administered to participants in one arm for the study
Drug: IMMU-132 plus Carboplatin infusion

First Posted Date: 2014-06-12

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Registration Number: NCT02161679

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Conditions: Chronic Lymphocytic Leukemia (CLL)

First Posted Date: 2014-05-13

Last Posted Date: 2014-10-28

Lead Sponsor: Gilead Sciences

Registration Number: NCT02136511

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇮🇹
Ospedale San Raffaele, Milano, Italy

and more 5 locations

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Drug: Presatovir placebo
Drug: Presatovir

First Posted Date: 2014-05-12

Last Posted Date: 2018-09-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 189

Registration Number: NCT02135614

Locations: 🇺🇸
William Beaumont, Royal Oak, Michigan, United States
🇺🇸
Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 40 locations

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

Phase 4

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: Sofosbuvir
Drug: RBV

First Posted Date: 2014-05-01

Last Posted Date: 2016-08-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 66

Registration Number: NCT02128542

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: FTC/TDF
Drug: F/TAF
Drug: Allowed third antiretroviral agent
Drug: FTC/TDF Placebo
Drug: F/TAF Placebo

First Posted Date: 2014-04-24

Last Posted Date: 2020-03-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 668

Registration Number: NCT02121795

Locations: 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸
Dupont Circle Physician's Group, Washington, District of Columbia, United States
🇺🇸
Whitman-Walker Health, Washington, District of Columbia, United States

and more 74 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy